Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

May 17, 2021 17 May, 2021

Sernova to Present at Global Partnership Family Office – HealthCare & Biotechnology TSX Showcase

May 17, 2021 9:00 AM ET

LONDON, ON – May 17, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the virtual Global Partnership Family Office – Healthcare & Biotechnology TSX Showcase on May 19th, 2021. The Showcase is hosted by London, UK based International Deal Gateway (IDG).

The event is by invitation only and includes a selected group of inspiring leaders from innovative public companies in the healthcare, biotechnology and life sciences sector. Five leading companies listed on the TSX or TSX Venture have been selected to present live, via video, to GPFO investors.

“Deal Gateway’s exclusive virtual events give innovative leaders the opportunity to introduce their companies to a very hard to reach audience of family offices and access new pools of capital in London, Geneva, Zurich and other key markets,” said Elizabeth Priestman, CEO of IDG.

“Sernova is delighted to have been selected by the TSX to present to this exclusive group of sophisticated investors,” said Dr. Philip Toleikis, President and CEO of Sernova. “This presentation aligns with our goal to increase the percentage of longer-term oriented institutional investors amongst our shareholder base who understand the value of innovative technologies. We look forward to presenting to them and outlining the potential of Sernova’s innovative regenerative medicine platform, including potentially providing a ‘functional cure” for diabetes and other chronic diseases.”

Following the event, a recording will be available at www.sernova.com.

Selected Company Achievements

● Integrated regenerative medicine therapeutic platform solution including an implantable device with local immune protection (Conformal Coating Technology) that could eliminate the need for immunosuppressive medications to protect cells from immune system attack.

● First and only regenerative medicine therapeutics platform company to demonstrate an implantable well- vascularized subcutaneous cell transplant device technology achieving persistent islet graft function and clinical benefit as presented in the most advanced study patients in its ongoing US Phase I/II diabetes clinical trial.

● Demonstrated preclinical proof-of-concept showing improvement in blood clotting with human cells using an ex vivo gene therapy approach for hemophilia A

● Demonstrated preclinical proof-of-concept with transplanted human thyroid tissue for management of hypothyroid disease.

● Multiple research collaborations in place with pharmaceutical industry leaders.

About Global Partnership Family Office (GPFO) and International Deal Gateway (IDG)

International Deal Gateway's Family Office Events provide a unique opportunity for public and private companies to gain access to an exclusive group of 2,400 ultra-high net worth investors and family offices throughout Europe through their long-standing relationship with GPFO. Together, IDG and GPFO look forward to hosting the TSX sponsored Healthcare & Biotechnology Showcase, a collection of extraordinary select companies working to improve health outcomes with a focus on longevity, healthcare, biotechnology and data.

GPFO has been the 'eyes and ears' of the global family office community for over a decade. Providing salient, timely and impartial briefings, insights and opportunities to its membership.

Dr. Michael J. Oliver, GPFO founder, "We have been delighted to grow our partnership with IDG over the years, providing our community with insights from the brightest minds and leaders from across the Atlantic, offering a bridge for many of our network who have deep familial and business ties to Canada and the US."

About Sernova

Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device, therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and immune protection technologies to improve the treatment and quality of life of people living with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

CONTACTS:

Sernova Corp

Dominic Gray

Head of Communications

(519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials and the potential of local immune protection technologies. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.